Abstract
Background There is a strong dose-response relationship between regular physical activity (PA) and stroke risk. However, this relationship is attenuated in the presence of cardiovascular risk. This study aimed to compare the dose-response relationship between PA and stroke between normo- and hypertensive individuals.
Methods A cohort study including 139,930 individuals was performed (median follow up: 6.75 years). Participants were stratified at baseline as hypertensive or normotensive and were categorised into quartiles of lowest (Q1) to highest (Q4) moderate-to-vigorous (MV), self-reported PA. Primary outcome was stroke. Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals. The main analyses were stratified on baseline blood pressure and adjusted for confounders. Additionally, hypertensives were stratified into medicated or not medicated.
Results Compared to Q1, adjusted HRs were 0.87 (0.69-1.10, P=0.23) for Q2, 0.75 (0.59-0.95, P=0.02) for Q3, and 0.94 (0.74-1.20, P=0.64) for Q4 in the total population. In the stratified analyses, HRs for individuals with normotension were 0.79 (0.50-1.25, P=0.32), 0.75 (0.48-1.18, P=0.22), 0.97 (0.62-1.51, P=0.90) for MVPA Q2 to Q4, respectively. In hypertensive individuals, HRs compared to Q1 were 0.89 (0.68-1.17, P=0.41), 0.74 (0.56-0.98, P=0.03), 0.92 (0.69-1.23, P=0.56) for Q2-Q4, respectively. There was no significant interaction between PA and hypertensive status. A smaller benefit of MVPA in medicated hypertensives compared to non-medicated was observed, however the dose-response association was similar.
Conclusion MVPA reduces stroke risk in the total population (Q3), which is not affected by the presence of hypertension. Use of anti-hypertensive medication may interfere with the impact of MVPA on stroke risk.
What is new?Presence of cardiovascular disease or cardiovascular disease risk factors may alter the dose-response relationship between regular physical activity and major adverse cardiovascular events (MACE) and mortality. No previous study has investigated whether hypertension per se alters the dose-response relationship between regular moderate-to-vigorous physical activity (MVPA) and stroke risk.
What is relevant?This large cohort study demonstrates the importance of regular MVPA on stroke risk reduction particularly in individuals with hypertension. Furthermore, this study provides preliminary indication that the use of antihypertensive medication may alter this association.
Clinical/Pathophysiological implications?The presence of hypertension does not alter the dose-response association between MVPA and stroke. Importantly, this highlights that MVPA is beneficial in reducing the risk of stroke, even in individuals diagnosed with hypertension. Although this cohort study cannot make solid conclusions on the influence of antihypertensive medication, this study reinforces the importance of regular physical activity on the clinical outcome of stroke.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is not a clinical trial
Funding Statement
EAB has received funding from the European Union?s Horizon 2020 research and innovation programme under the Marie Sk?odowska-Curie grant agreement No [101064851]. The Lifelines Biobank initiative received funding from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical Center Groningen [UMCG], University Groningen and the Northern Provinces of the Netherlands. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Lifelines Cohort study was conducted according to the principles of the Declaration of Helsinki and approved by the University Medical Centre Groningen Medical Ethical Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data can only be accessed by Statistics Netherlands
